method of treating or preventing inflammation or allergic reaction.

- Group III. Claim(s) 1-7, 10, and 18-44, drawn to a histamine or serotonin binding compound of Figure 3, nucleic acid molecule, vector, host cell, and method of treating or preventing inflammation or allergic reaction.
- Group IV. Claim(s) 1-7, 10, and 18-44, drawn to a histamine or serotonin binding compound of Figure 4, nucleic acid molecule, vector, host cell, and method of treating or preventing inflammation or allergic reaction.
- Group V. Claim(s) 8-9, drawn to a histamine or serotonin binding compound that comprises a cyclic peptide.
- Group VI. Claim(s) 50, drawn to transgenic animal that has been transformed by a nucleic acid molecule.
- Group VII. Claim(s) 51 and 18-44, drawn to a protein consisting of the Ra-Res amino acid sequence given in Figure 5.
- Group VIII. Claim(s) 51 and 18-44, drawn to a protein consisting of the Av-HBP amino acid sequence given in Figure 6.
- Group IX. Claim(s) 51 and 18-44, drawn to the Ih/Bm-HBP amino acid sequence given in Figure 7.
- Group X. Claim(s) 51 and 18-44, drawn to the Ih/Bm-HBP2 amino acid sequence given in Figure 8.
- Group XI. Claim(s) 51 and 18-44, drawn to the Ih/Bm-HBP3 amino acid sequence given in Figure 9.
- Group XII. Claim(s) 51 and 18-44, drawn to the Ih/Bm-HBP4 amino acid sequence given in Figure 10.
- Group XIII. Claim(s) 51 and 18-44, drawn to the Ih/Bm-HBP5 amino acid sequence given in Figure 11.

Responsive to the Requirement for restriction, Applicants elect to prosecute the invention of Group IV, Claims 1-7, 10, and 18-44, which are drawn to a histamine or serotonin binding compound of Figure 4, nucleic acid molecule, vector, host cell, and method of treating or preventing inflammation or allergic reaction.

Finally, the Examiner has further required the election of a distinct species of the claimed Group, wherein the binding site group is:

- a) a histamine or serotonin binding protein which has a binding site comprising amino acid residues Phe, Ile or Leu at position I, Trp at position II, and Asp or Glu at positions III and IV;
- b) a histamine or serotonin binding protein which has a binding site comprising amino acid residues Phe or Ile at residue I, Trp at residue II, and Asp or Glu at residues III and IV; and
- a histamine or serotonin binding protein which has a first binding site comprising amino acid residues Phe, Ile or Leu at position I, Trp at position II, and Asp or Glu at positions III and IV, and a second binding site comprising amino acid residues Phe or Ile at residue I, Trp at residue II, and Asp or Glu at residues II and IV.

The Applicant elects (c) a histamine or serotonin binding protein which has a first binding site comprising amino acid residues Phe, Ile or Leu at position I, Trp at position II, and Asp or Glu at positions III and IV, and a second binding site comprising amino acid residues Phe or Ile at residue I, Trp at residue II, and Asp or Glu at residues II and IV. Claims 1-7, 10, and 18-44 of Group IV are all readable on this elected species.

The Examiner has further required the election of a distinct species of the claimed Group, wherein the type of histamine/serotonin binding compound is:

- d) a histamine or serotonin binding compound which comprises a peptide; and
- e) a histamine or serotonin binding compound which comprises a synthetic compound.

The Applicant elects (e) a histamine or serotonin binding compound which comprises a synthetic compound. Claims 1-7, 10, 18-44 of Group IV are all readable on this elected species.

The Examiner has further required the election of a distinct species of the claimed Group, wherein the type of peptide fusion is:

f) a histamine or serotonin binding compound that is genetically fused to one or more peptides; and

g) a histamine or serotonin binding compound that is chemically fused to one or more peptides.

The Applicant elects (f) a histamine or serotonin binding compound that is genetically fused to one or more peptides. Claims 1-7, 10, 18-44 of Group IV are all readable on this elected species.

The Examiner has further required the election of a distinct species of the claimed Group, wherein the type of additional peptide in a composition is:

- h) a cysteinyl leukotriene;
- i) a platelet activating factor; and
- i) a thromboxane.

The Applicant elects (h) a cysteinyl leukotriene. Claims 1-7, 10, 18-44 of Group IV are all readable on this elected species.

No additional fees are believed to be necessitated by the foregoing Response. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 11-1153 for any underpayment, or credit any overages.

In view of the above, withdrawal of the Requirement for the Restriction is requested, and an early action on the merits of the Claims is courteously solicited.

Respectfully submitted,

DAVIDA. JACKSON Attorney for Applicant(s) Registration No. 26,742

KLAUBER & JACKSON 411 Hackensack Avenue Hackensack, New Jersey 07601 (201) 487-5800

Date: March 31, 2003